Hospira Hits New 52-Week High at $54.24 (HSP)
Hospira (NYSE:HSP) shares hit a new 52-week high on Monday , Analyst Ratings.Net reports. The stock traded as high as $54.24 and last traded at $52.63, with a volume of 2,558,816 shares trading hands. The stock had previously closed at $51.72.
A number of research firms have recently commented on HSP. Analysts at Deutsche Bank initiated coverage on shares of Hospira in a research note on Tuesday, July 22nd. They set a “hold” rating on the stock. Separately, analysts at Wells Fargo & Co. initiated coverage on shares of Hospira in a research note on Wednesday, June 11th. They set a “market perform” rating on the stock. Finally, analysts at Zacks upgraded shares of Hospira from a “neutral” rating to an “outperform” rating in a research note on Thursday, May 29th. They now have a $58.00 price target on the stock. One analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $45.50.
The stock has a 50-day moving average of $51.35 and a 200-day moving average of $46.08. The company has a market cap of $8.665 billion and a P/E ratio of 63.69.
Hospira (NYSE:HSP) last announced its earnings results on Wednesday, April 30th. The company reported $0.60 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.49 by $0.11. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the company posted $0.52 earnings per share. Hospira’s revenue was up 6.3% compared to the same quarter last year. On average, analysts predict that Hospira will post $2.22 earnings per share for the current fiscal year.
In other Hospira news, CFO Thomas E. Werner sold 10,000 shares of the stock on the open market in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $51.50, for a total transaction of $515,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Hospira, Inc (NYSE:HSP) is a provider of injectable drugs and infusion technologies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.